Wilmington PharmaTech Appoints Industry Veteran Kent Payne as Managing Director and Board Member
Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development and manufacturing organization (CRDMO) focused on complex custom small molecule API, today announced the appointment of Kent Payne, Ph.D., as Managing Director and Board Member. Dr. Payne, an Operating Partner at Curewell Capital, a healthcare-focused private equity firm, joins WPT’s leadership team following Curewell’s recent investment in the company, and will work closely with WPT’s Founder and CEO Hui-Yin “Harry” Li, Ph.D., to accelerate the company’s growth strategy, including expanding manufacturing capacity and capabilities in the U.S.
